APTO

Aptose Biosciences (APTO)

About Aptose Biosciences (APTO)

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Details

Daily high

$0.39

Daily low

$0.21

Price at open

$0.27

52 Week High

$2.68

52 Week Low

$0.13

Market cap

16.6M

Dividend yield

0.00%

Volume

306.2M

Avg. volume

19.4M

P/E ratio

-.09

Aptose Biosciences News